Barbara Joureau1, Josine Marieke de Winter1, Stefan Conijn1, Sylvia J P Bogaards1, Igor Kovacevic1, Albert Kalganov2, Malin Persson2,3, Johan Lindqvist4, Ger J M Stienen1, Thomas C Irving5, Weikang Ma5, Michaela Yuen1,6,7, Nigel F Clarke6,7, Dilson E Rassier2, Edoardo Malfatti8, Norma B Romero8, Alan H Beggs9, Coen A C Ottenheijm1,4. 1. Department of Physiology, VU University Medical Center Amsterdam, Amsterdam, the Netherlands. 2. Department of Kinesiology and Physical Education, McGill University, Montreal, Quebec, Canada. 3. Department of Physiology and Pharmacology, Karolinska Institute, Stockholm, Sweden. 4. Department of Molecular and Cellular Biology and Molecular Cardiovascular Research Program, University of Arizona, Tucson, AZ. 5. Biophysics Collaborative Access Team, Center for Synchrotron Radiation Research and Instrumentation, and Department of Biological Sciences, Illinois Institute of Technology, Chicago, IL. 6. Institute for Neuroscience and Muscle Research, Children's Hospital at Westmead, Westmead, New South Wales, Australia. 7. Discipline of Pediatrics and Child Health, University of Sydney, Sydney, New South Wales, Australia. 8. Pierre and Marie Curie University/University of Paris VI, Sorbonne Universities, National Institute of Health and Medical Research UMRS974, National Center for Scientific Research FRE3617, Center for Research in Myology, Pitié-Salpêtrière Hospital Group, Paris, France. 9. Division of Genetics and Genomics, Manton Center for Orphan Disease Research, Boston Children's Hospital, Harvard Medical School, Boston, MA.
Abstract
OBJECTIVE: Nemaline myopathy (NM) is one of the most common congenital nondystrophic myopathies and is characterized by muscle weakness, often from birth. Mutations in ACTA1 are a frequent cause of NM (ie, NEM3). ACTA1 encodes alpha-actin 1, the main constituent of the sarcomeric thin filament. The mechanisms by which mutations in ACTA1 contribute to muscle weakness in NEM3 are incompletely understood. We hypothesized that sarcomeric dysfunction contributes to muscle weakness in NEM3 patients. METHODS: To test this hypothesis, we performed contractility measurements in individual muscle fibers and myofibrils obtained from muscle biopsies of 14 NEM3 patients with different ACTA1 mutations. To identify the structural basis for impaired contractility, low angle X-ray diffraction and stimulated emission-depletion microscopy were applied. RESULTS: Our findings reveal that muscle fibers of NEM3 patients display a reduced maximal force-generating capacity, which is caused by dysfunctional sarcomere contractility in the majority of patients, as revealed by contractility measurements in myofibrils. Low angle X-ray diffraction and stimulated emission-depletion microscopy indicate that dysfunctional sarcomere contractility in NEM3 patients involves a lower number of myosin heads binding to actin during muscle activation. This lower number is not the result of reduced thin filament length. Interestingly, the calcium sensitivity of force is unaffected in some patients, but decreased in others. INTERPRETATION: Dysfunctional sarcomere contractility is an important contributor to muscle weakness in the majority of NEM3 patients. This information is crucial for patient stratification in future clinical trials. Ann Neurol 2018;83:269-282.
OBJECTIVE:Nemaline myopathy (NM) is one of the most common congenital nondystrophic myopathies and is characterized by muscle weakness, often from birth. Mutations in ACTA1 are a frequent cause of NM (ie, NEM3). ACTA1 encodes alpha-actin 1, the main constituent of the sarcomeric thin filament. The mechanisms by which mutations in ACTA1 contribute to muscle weakness in NEM3 are incompletely understood. We hypothesized that sarcomeric dysfunction contributes to muscle weakness in NEM3patients. METHODS: To test this hypothesis, we performed contractility measurements in individual muscle fibers and myofibrils obtained from muscle biopsies of 14 NEM3patients with different ACTA1 mutations. To identify the structural basis for impaired contractility, low angle X-ray diffraction and stimulated emission-depletion microscopy were applied. RESULTS: Our findings reveal that muscle fibers of NEM3patients display a reduced maximal force-generating capacity, which is caused by dysfunctional sarcomere contractility in the majority of patients, as revealed by contractility measurements in myofibrils. Low angle X-ray diffraction and stimulated emission-depletion microscopy indicate that dysfunctional sarcomere contractility in NEM3patients involves a lower number of myosin heads binding to actin during muscle activation. This lower number is not the result of reduced thin filament length. Interestingly, the calcium sensitivity of force is unaffected in some patients, but decreased in others. INTERPRETATION: Dysfunctional sarcomere contractility is an important contributor to muscle weakness in the majority of NEM3patients. This information is crucial for patient stratification in future clinical trials. Ann Neurol 2018;83:269-282.
Authors: David O Hutchinson; Amanda Charlton; Nigel G Laing; Biljana Ilkovski; Kathryn N North Journal: Neuromuscul Disord Date: 2006-01-19 Impact factor: 4.296
Authors: Coen A C Ottenheijm; Pleuni Hooijman; Elizabeth T DeChene; Ger J Stienen; Alan H Beggs; Henk Granzier Journal: J Struct Biol Date: 2009-11-26 Impact factor: 2.867
Authors: Coen A C Ottenheijm; Christian C Witt; Ger J Stienen; Siegfried Labeit; Alan H Beggs; Henk Granzier Journal: Hum Mol Genet Date: 2009-04-04 Impact factor: 6.150
Authors: John C Sparrow; Kristen J Nowak; Hayley J Durling; Alan H Beggs; Carina Wallgren-Pettersson; Norma Romero; Ikuya Nonaka; Nigel G Laing Journal: Neuromuscul Disord Date: 2003-09 Impact factor: 4.296
Authors: Gianina Ravenscroft; Connie Jackaman; Caroline A Sewry; Elyshia McNamara; Sarah E Squire; Allyson C Potter; John Papadimitriou; Lisa M Griffiths; Anthony J Bakker; Kay E Davies; Nigel G Laing; Kristen J Nowak Journal: PLoS One Date: 2011-12-09 Impact factor: 3.240
Authors: Martijn van de Locht; Sandra Donkervoort; Josine M de Winter; Stefan Conijn; Leon Begthel; Benno Kusters; Payam Mohassel; Ying Hu; Livija Medne; Colin Quinn; Steven A Moore; A Reghan Foley; Gwimoon Seo; Darren T Hwee; Fady I Malik; Thomas Irving; Weikang Ma; Henk L Granzier; Erik-Jan Kamsteeg; Kalyan Immadisetty; Peter Kekenes-Huskey; José R Pinto; Nicol Voermans; Carsten G Bönnemann; Coen Ac Ottenheijm Journal: J Clin Invest Date: 2021-05-03 Impact factor: 14.808
Authors: Josine M de Winter; Charlotte Gineste; Elisa Minardi; Lorenza Brocca; Maira Rossi; Tamara Borsboom; Alan H Beggs; Monique Bernard; David Bendahan; Darren T Hwee; Fady I Malik; Maria Antonietta Pellegrino; Roberto Bottinelli; Julien Gondin; Coen A C Ottenheijm Journal: Hum Mol Genet Date: 2021-06-26 Impact factor: 6.150
Authors: Joshua S Clayton; Elyshia L McNamara; Hayley Goullee; Stefan Conijn; Keren Muthsam; Gabrielle C Musk; David Coote; James Kijas; Alison C Testa; Rhonda L Taylor; Amanda J O'Hara; David Groth; Coen Ottenheijm; Gianina Ravenscroft; Nigel G Laing; Kristen J Nowak Journal: Acta Neuropathol Commun Date: 2020-08-20 Impact factor: 7.801